GTPase
The hydrolysis of guanosine triphosphate (GTP) is a key process in numerous vital processes. Intracellular signal transduction, protein synthesis, vesicular and nucleocytoplasmic transport, protein targeting, growth control and differentiation, are all, among other processes, controlled enzymatically by the conversion of GTP into GDP and inorganic phosphate. GTPases are the molecular switches that catalyze this reaction. They cycle between two conformational states: one bound to GTP ('active' state), the other bound to GDP ('inactive' state), and they hydrolyze GTP to GDPand inorganic phosphate. In the 'on' (GTP) state, GTPases recognize target proteins and generate a response until GTP hydrolysis returns the switch to the 'off' state[1]. GTPases can be classified into six families of heterotrimeric G-protein, small monomeric, protein-synthesizing, signal-recognition-particle, dynamin, and tubulin GTPases (EC 3.6.5.1 – EC 3.6.5.6 respectively). GTP-hydrolysis by GTPases is intrinsically very slow but can be accelerated by orders of magnitude upon interaction with GTPase-activating proteins (GAPs)[2]. In order to bring the GTPase back in the GTP bound ‘on’ state, so called guanine nucleotide exchange factors (GEFs), which cause the GDP to dissociate from the GTPase, leading to its association with new GTP.
[1] S. Etienne-Manneville, A. Hall. Rho GTPases in cell biology. Nature 2002, 420, 629-635.
[2] K. Scheffzek, M.R. Ahmadian, Wittinghofer. GTPase-activating proteins: helping hands to complement an active site. Trends Biochem Sci. 1998, 23, 257-262.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3575 | AMG510 | Highly potent, selective, and orally bioavailable KRAS-G12C inhibitor | €90.00 | |
3084 | ARS-1620 | Potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor | €145.00 | |
3053 | BAY-293 | Potent, selective and cell-active inhibitor of KRAS-SOS1 interaction | €140.00 | |
3471 | BI-3406 | Inhibitor of KRAS/Son of Sevenless 1 (SOS1) interaction | Inquire | |
2397 | BQU 57 | Inhibitor of the RAS-like small GTPases RalA and RalB | €125.00 | |
3987 | CASIN | Selective Cdc42 inhibitor | €140.00 | |
2753 | CCG 232601 | Rho/MRTF/SRF transcriptional pathway inhibitor | €160.00 | |
1931 | CCG 50014 | Inhibitor of RGS proteins (RGS4 selective) | €90.00 | |
3092 | CCG-203971 | Rho/MRTF/SRF transcriptional pathway inhibitor | €60.00 | |
3069 | CCG-222740 | Potent and selective Rho/MRTF/SRF transcriptional pathway inhibitor | €145.00 | |
2184 | CID 1067700 | First inhibitor of Rab7 GTPase | €125.00 | |
3879 | Dynasore | Noncompetitive cell-permeable dynamin inhibitor | €80.00 | |
2351 | EHop 016 | Rac GTPase inhibitor specific for Rac1 and Rac3 | €85.00 | |
2829 | Fendiline hydrochloride | KRAS inhibitor; Ca2+ channel blocker (L-type voltage gated) | €50.00 | |
3768 | GDC-6036 | Inhibitor of KRAS G12C | Inquire | |
4197 | Golgicide A | Potent, highly specific and reversible inhibitor of GBF1 | €95.00 | |
4029 | Hydroxy-Dynasore | Cell-permeable dynamin inhibitor; MUS81-EME1/2 inhibitor | Recently added | €90.00 |
4160 | IGGi-11me | Membrane permeable prodrug of IGGi-11; GIV-Gαi inhibitor | €140.00 | |
2302 | Kobe 0065 | HRAS inhibitor | €70.00 | |
2777 | MBQ-167 | Dual Rac and Cdc42 inhibitor | €105.00 | |
2017 | ML 210 | Chemical probe that selectively kills cells induced to express mutant RAS | €115.00 | |
3761 | MRTX1133 | First-in-class, noncovalent, selective & reversible inhibitor of KRASG12D mutant | €220.00 | |
3733 | MRTX1257 | Irreversible covalent inhibitor of KRAS G12C | Inquire | |
4036 | MRTX849 | Potent, mutation-selective, and irreversible covalent inhibitor of KRAS-G12C | Inquire | |
3622 | NAV-2729 | Dual Arf1/Arf6 inhibitor; FATP2 inhibitor | €80.00 | |
1578 | NSC 23766 | Rac1 inhibitor | €110.00 | |
2393 | NSC 756093 | Potent in vitro inhibitor of GBP1:PIM1 interaction | €125.00 | |
2396 | RBC 8 | Inhibitor of the RAS-like small GTPases RalA and RalB | €105.00 | |
2138 | ZCL 278 | Cdc42 GTPase inhibitor, targeting Cdc42–ITSN interaction | €105.00 | |
3790 | ZINC69391 | Specific Rac1 inhibitor | €110.00 |